These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17082245)

  • 21. Estimation of economic costs associated with transfusion dependence in adults with MDS.
    Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
    Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature.
    van Nooten FE; Green J; Brown R; Finkelstein FO; Wish J
    J Med Econ; 2010; 13(2):241-56. PubMed ID: 20438399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of activated protein C in real-life clinical practice.
    Dhainaut JF; Payet S; Vallet B; França LR; Annane D; Bollaert PE; Le Tulzo Y; Runge I; Malledant Y; Guidet B; Le Lay K; Launois R;
    Crit Care; 2007; 11(5):R99. PubMed ID: 17822547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health service utilization among Alzheimer's disease patients: evidence from managed care.
    Frytak JR; Henk HJ; Zhao Y; Bowman L; Flynn JA; Nelson M
    Alzheimers Dement; 2008 Sep; 4(5):361-7. PubMed ID: 18790463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glaucoma in the United States and europe: predicting costs and surgical rates based upon stage of disease.
    Lee PP; Kelly SP; Mills RP; Traverso CE; Walt JG; Doyle JJ; Katz LM; Siegartel LR;
    J Glaucoma; 2007 Aug; 16(5):471-8. PubMed ID: 17700290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic non-small cell lung cancer: costs associated with disease progression.
    Fox KM; Brooks JM; Kim J
    Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stabilization of glomerular filtration rate in advanced chronic kidney disease: a two-year follow-up of a cohort of chronic kidney disease patients stages 4 and 5.
    Serrano A; Huang J; Ghossein C; Nishi L; Gangavathi A; Madhan V; Ramadugu P; Ahya SN; Paparello J; Khosla N; Schlueter W; Batlle D
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):105-12. PubMed ID: 17200050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
    Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
    J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of chronic kidney disease stages 3-5 among acute medical admissions: another opportunity for screening.
    Annear NM; Banerjee D; Joseph J; Harries TH; Rahman S; Eastwood JB
    QJM; 2008 Feb; 101(2):91-7. PubMed ID: 18184667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
    Axelsson J; Witasp A; Carrero JJ; Qureshi AR; Suliman ME; Heimbürger O; Bárány P; Lindholm B; Alvestrand A; Schalling M; Nordfors L; Stenvinkel P
    Am J Kidney Dis; 2007 Feb; 49(2):237-44. PubMed ID: 17261426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.
    Papatheofanis F; Bookhart BK; Muser E; Piech CT
    J Occup Environ Med; 2008 May; 50(5):584-9. PubMed ID: 18469628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severity of chronic kidney disease as a risk factor for operative mortality in nonemergent patients in the California coronary artery bypass graft surgery outcomes reporting program.
    Yeo KK; Li Z; Yeun JY; Amsterdam E
    Am J Cardiol; 2008 May; 101(9):1269-74. PubMed ID: 18435956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.
    Levin A; Djurdjev O; Beaulieu M; Er L
    Am J Kidney Dis; 2008 Oct; 52(4):661-71. PubMed ID: 18805347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease progression and outcomes in type 1 diabetic kidney transplant recipients based on posttransplantation CKD staging.
    Smavatkul C; Pascual J; Desai AG; Samaniego M; Becker BN; Djamali A
    Am J Kidney Dis; 2007 Oct; 50(4):631-40. PubMed ID: 17900463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction.
    Lambert ND; Sacrinty MT; Ketch TR; Turner SJ; Santos RM; Daniel KR; Applegate RJ; Kutcher MA; Sane DC
    Am Heart J; 2009 Apr; 157(4):688-94. PubMed ID: 19332197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.